MedDataX Logo

Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

NCT ID: NCT01451424

Last Updated: 2014-08-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-02-29

Study Completion Date

2013-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the safety, pharmacokinetics and efficacy of 4 doses (3, 6, 12, 24 mg) of Proellex in premenopausal women with uterine fibroids confirmed by ultrasound. Drug will be administered vaginally.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a phase II, 5 arm study with a 12 week active dosing period. The study will be conducted in 2 stages. In the first stage, the first 6 women to be enrolled will be treated at the 12mg dose level, and in addition to the other required study assessments will be monitored with a 24-hour PK assessment on Day 14, and daily trough assessments for the first 14 days. If, at Visit 3, the Cmax or AUC of any subject treated at 12mg exceeds the mean observed for the highest safe oral dose administered in the ZP-204 study, all subjects enrolled at the 12mg level will be discontinued, no further patients will be treated at this dose level, and the 6mg vaginal dose will be assessed in a similar fashion. In the second stage, the remaining subjects will be randomized to a dose of 3, 6, 12 or 24 mg.

For all subjects there will be a 4-6 week placebo run-in period, to establish baseline parameters (bleeding and quality of life) followed by treatment at one of three single-blind Proellex doses (3, 6 or 12 mg daily, administered vaginally in capsule form.) The primary efficacy endpoint will be bleeding assessed using the Pictorial Blood Loss Assessment Chart (PBAC) after 12 or 16 weeks of treatment. The secondary endpoints will be changes in size of uterine fibroids assessed by MRI and improvement in quality of life assessed using the Uterine Fibroid Symptom and Health-Related Quality of Life questionnaire (UFSQOL0. Safety endpoints include significant adverse events, changes in physical examination results, and/or clinical laboratory results significantly outside of normal range. For subjects enrolled in Stage 2, PK will be assessed after the first and last doses and trough levels every 2 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uterine Fibroids

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Proellex 12 mg PK group

Subjects receiving 12 mg Proellex administered vaginally, and completing a PK arm consisting of 1 x 24 hr PK of Proellex, 14 days of daily Proellex trough measurements, and 1 x 24 hr PK of Proellex after 14 days of daily dosing. 12 mg PK subjects will continue with the protocol as written after the first 2 week period and will be treated for a total of 16 weeks.

Group Type EXPERIMENTAL

Proellex

Intervention Type DRUG

vaginal suppository, daily, for 12 weeks

Proellex 12 mg per protocol

Subjects receiving 12 mg Proellex daily, vaginally for 12 weeks

Group Type EXPERIMENTAL

Proellex

Intervention Type DRUG

vaginal suppository, daily, for 12 weeks

Proellex 6 mg per protocol

Subjects receiving 6 mg Proellex daily, vaginally for 12 weeks

Group Type EXPERIMENTAL

Proellex

Intervention Type DRUG

vaginal suppository, daily, for 12 weeks

Proellex 3 mg per protocol

Subjects will receive 3 mg Proellex daily, vaginally for 12 weeks.

Group Type EXPERIMENTAL

Proellex

Intervention Type DRUG

vaginal suppository, daily, for 12 weeks

24 mg Proellex

24 mg vaginal Proellex daily for 16 weeks

Group Type EXPERIMENTAL

Proellex

Intervention Type DRUG

vaginal suppository, daily, for 12 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Proellex

vaginal suppository, daily, for 12 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Telapristone acetate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adult females between 18 and 47 years of age with uterine fibroids confirmed by ultrasound.
* Normal transvaginal ultrasound (other than for presence of fibroids)
* History of menstrual events occurring in regular cycles
* Agreement not to attempt to become pregnant
* Agreement to limit alcohol consumption to no more than 2 drinks per week and to avoid alcohol consumption within 48 hours before each visit
* Ability to complete a daily subject diary
* Willing to discontinue hormonal contraceptives and consent to use of double barrier contraceptive techniques over the course of the study.
* Has a negative pregnancy test at the Screening and Baseline visits An exception for the pregnancy test requirement will be granted for subjects reporting surgical sterilization in medical history
* A Body Mass Index (BMI) between 18 and 39 inclusive
* Is available for all treatment and follow-up visits.

Exclusion Criteria

* Subject is a post-menopausal woman, defined as either; six (6) months or more (immediately prior to screening visit) without a menstrual period, or prior hysterectomy and/or oophorectomy
* Subject is pregnant or lactating or is attempting or expecting to become pregnant during the 6 month study period
* Women with abnormally high liver enzymes or liver disease. (ALT or AST exceeding 1.5xULN AND total bilirubin exceeding 1.5xULN at screening and confirmed on repeat).
* Received an investigational drug in the 30 days prior to the screening for this study
* Women with a history of PCOS
* Concurrent use of any testosterone, progestin, androgen, estrogen, anabolic steroids, DHEA or hormonal products for at least 2 weeks prior to screening and during the study.
* Use of oral contraceptives in the preceding 2 weeks. Use of Depo-Provera® in the preceding 6 months.
* Has an IUD in place
* Women currently using narcotics
* Women currently taking spironolactone
* Infectious disease screen is positive for HIV or Hepatitis A, B or C
* Clinically significant abnormal findings on screening examination or any condition which in the opinion of the investigator would interfere with the participant's ability to comply with the study instructions or endanger the participant if she took part in the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

47 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Repros Therapeutics Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ronald D Wiehle, PhD

Role: STUDY_DIRECTOR

Repros Therapeutics Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cetero Research

Miami Gardens, Florida, United States

Site Status

Advances in Health

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

http://www.reprosrx.com

Repros Therapeutics Inc corporate website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ZPV-200

Identifier Type: -

Identifier Source: org_study_id